Company
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Regeneron Pharmaceuticals Inc is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.
37 stories
Archive
Introducing the First AI Model That Translates 100 Languages Without Relying on English
•Facebook AI is introducing M2M-100, the first multilingual machine translation (MMT) model that can translate between any pair of 100 languages without relying on English data. It’s open sourced here.
CytoDyn appoints pharma industry veteran Dr Seenu Srinivasan as its executive director of CMC Regulatory Affairs
Dr Srinivasan is a former director of CMC Regulatory Affairs for Regeneron Pharmaceuticals and has 30 years of broad regulatory and drug development experience
Regeneron antibody cocktail cuts risk of death for patients in hospital, study finds
Researchers at the University of Oxford analysed the drug as part of the wider RECOVERY trial, which has been investigating potential treatment for COVID-19
Tiziana Life Sciences: Wall Street's HC Wainwright repeats 'buy' call and US$11 price target after Covid trial completion and hiring of heavy-hitting chief medical officer
HC Wainwright's analyst Raghuram Selvaraju provided his assessment of recent developments
Investments and investor services
Regeneron Pharmaceuticals tops 3Q earnings and revenue estimates; shares edge higher
The drugmaker is trying to grow and diversity its business
Clearside Biomedical shares slide after failed Phase 3 trial, but a plan B is in the works
Its Phase 3 clinical trial of eye disease drug Xipere failed to meet its primary endpoint
Shares in bluebird bio soar after it strikes partnership with Regeneron to work on immune cell therapies
Investors gave a thumbs up to the deal, which allows the Massachusetts-based biotech to split R&D costs with Regeneron on its lead cancer products
Investments and investor services
Wall Street ignores Trump’s call for lower drug prices, Dow industrials extend rally to seventh session
The tech-heavy Nasdaq bucked the trend and fell, helped lower by Symantec's disastrous showing
Regeneron higher after key drugs help deliver market-beating fourth quarter
The company’s key drugs – Praluent and Dupixent, and sales of Eyelea in the US – helped to lift the numbers for the quarter
Abbvie shares rising in New York on eczema drug news
The news led to a fall in rival Regeneron (NASDAQ:REGN), which shed over 5.6%
Merck and Gilead among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
Amgen up after judge rules rivals must pull a competing cholesterol drug off the market
District Judge Sue Robinson in Delaware announced a ban on Regeneron and Sanofi from selling their cholesterol drug, Praluent on the grounds of patent infringement.
US stocks clinch record highs, Dow skids (just) shy of 20,000 after jobs report
US stocks clinched fresh record highs on Friday, with the Dow coming within a hair’s breadth of 20,000 – which can only have been helped by Goldman Sach’s shares driving 1.5% higher
US stocks end lower as oil wanes, Fed in focus
US stocks ended lower on Monday as oil price gains waned and investors grew ever more anxious ahead of the Fed’s rate decision mid-week
Archive
Trending: Trump pledges to fight the drug companies
After his Nov. 9 victory investors jumped out of tech stocks and flocked to banks expected to benefit from deregulation, gun-makers on the hope that he won’t curb their sales, and pharmaceutical stocks on the understanding that Trump was ne
US stocks hit record highs as Dow adds 300 points, but pharma sink
US stocks hit fresh record highs on Wednesday, with the S&P 500 marking its biggest single-day gains since the presidential elections, as investors largely shrugged off declines in health care stocks
Pharmas Regeneron and Teva shares hit by FDA order
Shares of Regeneron Pharmaceuticals and Teva Pharmaceuticals were hit Monday by news of a clinical trial setback for a new pain drug they are co-developing
Teva and Regeneron to commercialise Fasinumab for chronic pain
Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. are teaming up to develop and commercialise globally commercialize fasinumab, Regeneron’s investigational NGF antibody in Phase 3 clinical development for osteoarthriti
Archive
S&P 500 caps solid week
The S&P enjoyed it best week for a month, while small and mid-caps also made progress.
Stocks sleep-walking towards the weekend
The March jobs report has perked up the blue-chips a little but the rest of the market seems indifferent
Wall Street extends slump as Fed president indicates September rate hike likely
Wall Street fell deeper today, as one Federal Reserve president indicated a September interest-rate hike is likely unless there’s a significant deterioration in the economy. The S&P 500 (INDEXSP:.INX) skidded 0.2 percent to 2,094.
U.S. stock-index futures drop as investors eye jobs report; CVS slides
U.S. stock index futures were lower today as investors await key jobs reports due later in the week. Futures for the Dow Jones Industrial Average lost 0.2 percent to 17,475, while those for the S&P 500 index skidded 0.3 percent to 2,085
Wall Street breaks 5-day losing run as investors look for tomorrow’s Fed statement
U.S. stocks halted the five-day losing streak today, as investors looked past softer economic reports and a continued rout in China’s stock market, and waited for the outcome of the two-day Federal Reserve. The S&P 500 (INDEXSP:.I
Wall Street on track to end 5-day rout as China selloff stalls
Wall Street is poised to end a five-session losing streak, amid better-than-forecast earnings, as Chinese equities pulled back from a selloff, and ahead of a highly anticipated Federal Reserve meeting. Futures for the Dow Jones Industrial A